THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO
THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE
THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICIATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES OF CREO MEDICAL GROUP PLC.
Creo Medical Group plc
("Creo" or the "Company")
Extension of Retail Offer Closing Date
Further to the announcement made on 30 September 2024 (RNS No 3043G) regarding the Retail Offer, the Company announces that it is extending the time allowed for existing retail shareholders to participate in the Retail Offer.
Under the revised timetable, the Retail Offer will now close at 4.30 p.m. on 17 October 2024 (previously 4.30 p.m. on 7 October). No other changes to the timetable have been made.
The change in timetable does not impact applications already made in the Retail Offer, and these continue to have effect and remain binding.
Revised Expected Timetable for the Fundraising
Latest time and date for receipt of Forms of Proxy and CREST voting instructions |
10.00 a.m. on 16 October 2024 |
Closing of the Retail Offer and announcement of the result of the Retail Offer |
4.30 p.m. on 17 October 2024 |
General Meeting |
10.00 a.m. on 18 October 2024 |
Results of the General Meeting announced |
18 October 2024 |
Admission of the New Ordinary Shares to trading on AIM and commencement of dealings |
8.00 a.m. on 21 October 2024 |
Where applicable, expected date for CREST accounts to be credited in respect of New Ordinary Shares in uncertificated form |
8.00 a.m. on 21 October 2024 |
Where applicable, expected date for despatch of definitive share certificates for New Ordinary Shares in certificated form |
By 3 November 2024 |
For further information, please visit www.creomedical.com or contact:
Creo Medical Group plc |
|
|||
Richard Rees (CFO) |
+44 (0)1291 606 005 |
|
||
|
||||
Cavendish Capital Markets Limited (Nominated Adviser, Joint Bookrunner and Joint Broker) |
+44 (0)20 7220 0500 |
|
||
Stephen Keys / Camilla Hume / George Lawson (NOMAD) |
|
|
||
Michael Johnson (Sales) |
|
|
||
|
|
|||
Deutsche Numis (Joint Bookrunner and Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown William Baunton (ECM) |
+44 (0)20 7260 1000 |
|
||
|
|
|
||
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
|
||
Paul McManus / Sam Allen / Phillip Marriage |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7867 984 082 |
|
||
|
|
|
|
|
Further information on the Company can be found on its website at: https://www.creomedical.com/en/investors/
The Company's LEI is 213800H188ZDCWWXFA21
This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.
Important Notices
The Retail Offer is only open to investors in the
This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from
The Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of
This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in
The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
Each of Cavendish and Numis Securities Limited (t/a Deutsche Numis) ("Deutsche Numis") is authorised and regulated in the
The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.
Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.
These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. Each of the Company, Cavendish and Deutsche Numis expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.
The information in this announcement is for background purposes only and does not purport to be full or complete. None of Cavendish, Deutsche Numis or any of their respective affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Each of Cavendish, Deutsche Numis and their respective affiliates, accordingly disclaims all and any liability whether arising in tort, contract or otherwise which it might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.
Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than London Stock Exchange.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.